Dr. Mark Frohlich is senior vice president of clinical affairs and chief medical officer at Dendreon Corp., a publicly-traded Seattle-based biotech company. He previously served as Dendreon's vice president of clinical affairs and before that was the company's senior medical director. Prior to joining Dendreon, Dr. Frohlich was vice president and medical director at biotech firm Xcyte Therapies. He also has a noted academic background. Before joining the private sector, he was an assistant professor in the division of hematology/oncology at the University of California, San Francisco, where he specialized in urologic oncology. Dr. Frohlich did his post doctoral training in oncology at the University of California, San Francisco. He received his BS from Yale University in electrical engineering and economics and his M.D. from Harvard Medical School.